| Identification | Back Directory | [Name]
[1-(3-chlorophenyl)triazol-4-yl]-thiomorpholino-methanone | [CAS]
951612-19-4 | [Synonyms]
L524-0366
L524 0366,L5240366,L-524-0366
[1-(3-chlorophenyl)triazol-4-yl]-thiomorpholino-methanone
(1-(3-Chlorophenyl)-1H-1,2,3-triazol-4-yl)(thiomorpholino)methanone
Methanone, [1-(3-chlorophenyl)-1H-1,2,3-triazol-4-yl]-4-thiomorpholinyl- | [Molecular Formula]
C13H13ClN4OS | [MOL File]
951612-19-4.mol | [Molecular Weight]
308.79 |
| Chemical Properties | Back Directory | [storage temp. ]
-20°C (des.) | [solubility ]
Soluble in DMSO (up to 14 mg/ml with warming) or in Ethanol (up to 2 mg/ml with warming). | [form ]
solid | [color ]
Beige | [Stability:]
Stable for 2 years from date of purchsae as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 3 months. | [InChI]
1S/C13H13ClN4OS/c14-10-2-1-3-11(8-10)18-9-12(15-16-18)13(19)17-4-6-20-7-5-17/h1-3,8-9H,4-7H2 | [InChIKey]
ZOBDTKWDYMRKPF-UHFFFAOYSA-N | [SMILES]
C1CSCCN1C(=O)C2=CN(N=N2)C3=CC(=CC=C3)Cl |
| Hazard Information | Back Directory | [Description]
L524-0366 (951612-19-4) is an Fn14 antagonist. Competes with TNF-like weak inducer of apoptosis (TWEAK) C-terminal/extracellular TNF homology domain (THD) for Fn14 binding (KD?= 7.12 μM). It specifically inhibits TWEAK-Fn14-mediated NFκB activation. L524-0366 completely suppressed TWEAK-induced T98G cell migration (10 μM) without cytotoxicity up to 50 μM.1?L524-0366 is the first compound known to interfere with the TWEAK/Fn14 interaction and may serve as a lead compound for the development of new therapeutics.2 | [Uses]
TWEAK-Fn14-IN-1 (Compound L524-0366) is a specific dose-dependent TWEAK-Fn14 inhibitor. TWEAK-Fn14-IN-1 binds specifically to the Fn14 surface with a KD of 7.12 μM. TWEAK-Fn14-IN-1 inhibits TWEAK induced glioma cell migration without any potential cytotoxic effects[1]. | [References]
1) Dhruv?et al. (2013),?Structural basis and targeting of the interaction between fibroblast growth factor-inducible 14 and tumor necrosis factor-like weak inducer of apoptosis; J. Biol. Chem.,?288?32261
2) Cheng?et al. (2013),?TWEAK/Fn14 Axis-Targeted Therapeutics: Moving Basic Science Discoveries to the Clinic; Front. Immunol.,?4?473 |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|